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Dysregulation of the REarranged during Transfection proto-oncogene (RET) pathway and microRNA
(miRNAs) are crucial for the development of medullary thyroid carcinomas (MTC). Here we demon-
strate that miR-129-5p is down-regulated in MTC tissues and cell lines and inhibits RET expression
by directly binding its 30 untranslated regions. Ectopic expression of miR-129-5p signiﬁcantly
decreases cell growth, induces apoptosis and suppresses migration ability in MTC cells through
decreasing the phosphorylated AKT, thus functioning as a tumor suppressor. These ﬁndings give
new clues for understanding MTC carcinogenesis and may help in developing a therapeutic
approach for the treatment of RET-activated MTC.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction therapeutic target for MTC [3]. Clinical trials of tyrosine kinaseMedullary thyroid carcinoma (MTC), arising from the parafollic-
ular calcitonin-producing C cells of the thyroid gland, accounts for
5–7% of all thyroid malignancies [1,2]. MTC mostly occurs as a
sporadic entity (75%), but also in hereditary (25%) [2]. The REar-
ranged during Transfection (RET) proto-oncogene, which encodes
the RET receptor tyrosine kinase, has been shown to be mutated
frequently and plays important roles in the pathogenesis of MTC
[3]. Activating mutations of RET function as oncogenes and have
essential roles in cell survival, apoptosis and proliferation through
mediating the activation of multiple signal pathways, including the
PI3K/AKT pathways [4]. Thus, RET has become an importantinhibitors (TKIs) targeting RET have shown efﬁcacy, but recent
study reported that TKIs targeting RET failed to cure MTC because
of the development of resistance [5]. Therefore, it is important to
develop a promising therapeutic strategy against MTC and a better
understanding of molecular regulatory mechanism of RET may be
helpful for the treatment of MTC [6].
MicroRNAs (miRNAs) are a class of small non-coding RNAs of
18–24 nucleotides, which are believed to negatively regulate gene
expression by binding the 30 untranslated regions (UTRs) of up to
60% of human mRNA by translational inhibition and destabiliza-
tion of mRNAs [7]. Recent studies have shown that miRNAs are
frequently misregulated in human cancers and act as either potent
oncogenes or tumor suppressor genes [7]. MiRNAs have also been
reported to be dysregulated in thyroid cancers and responsible for
tumor initiation and progression [8–13]. For example, up-regula-
tion of miR-221, miR-222 in thyroid carcinoma can directly
down-regulate the expression of an important regulator of cell
cycle, P27Kip1, thus involving in the pathogenesis of thyroid can-
cer [10,11]. Over-expression of miR-375 and miR-10a and under-
expression of miR-455 were found in MTC, and the differential
expression of these miRNAs may be important for tumor
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dysregulated miRNA proﬁles have been reported to be related to
RET status and prognosis in patients with MTC [13].
In this study, we aimed to investigate whether the expression of
RET was regulated by miRNAs and their biological role of the
dysregulated miRNAs in MTC cells.
2. Materials and methods
2.1. Human tissue specimens, cell culture and transfections
Twelve paired human MTC tissues and adjacent normal parts
were obtained from Hebei United University Afﬁliated Hospital.
The study was approved by the local ethics committee at Hebei
United University. All of the samples conﬁrmed by pathology were
collected and frozen in liquid nitrogen and then stored at 80 C.
Human MTC cell lines TT and MZ-CRC-1 harboring the oncogenic
point mutations of RET (C634W and M918T respectively) were
used in this study. TT cells were maintained in RPMI 1640 medium
(GIBCO, NY, USA), and MZ-CRC-1 cells were grown in DMEM (GIB-
CO). All media was supplemented with 10% fetal bovine serum
(Sigma–Aldrich, St Louis, USA), 2 nM glutamine and 105 U/l penicil-
lin–streptomycin. Both cells were grown in a 37 C incubator
supplied with 95% air and 5% carbon dioxide. All transfections were
done using Lipofectamine 2000 (Invitrogen, CA, USA) according to
the manufacturer’s protocol.
2.2. RNA extraction and quantitative reverse transcription PCR
(qRT-PCR)
RNA from cells or tissue samples was isolated by using the
mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA), according
to the manufacturer’s instructions. Two micrograms of large RNAs
(larger than 200 nt) or 1 lg of small RNAs (smaller than 200 nt)
were mixed with oligo (dT) or miRNA speciﬁc stem-loop RT
primers (miR-129-5p RT primer and U6 RT primer, Table 1) respec-
tively and reverse transcribed to cDNA using First Strand cDNA
Synthesis Kit (Fermentas, Burlington, Canada). These cDNAs were
subjected to qPCR using SYBR premix Ex Taq kit (TaKaRa, Dalian,
China) to detect the expression of RET mRNA or miR-129-5p
respectively. For RET mRNA expression, paired primers (RET-Fwd
and RET-Rev) were used with the level of glyceraldehyde phos-
phate dehydrogenase (GAPDH) mRNA as an endogenous referenceTable 1
The primers used in the experiments.
Name Sequen
MiR-129-5p-RT primer GTCGTA
MiR-129-5p-Fwd CTTTTT
U6-RT primer GTCGTA
U6-Fwd TGCGG
Rev GTGCAG
Pri-miR-129-5p-S GCCGG
Pri-miR-129-5p-AS GTCGAA
RET-HindIII-S CTAGAA
RET-EcoRI-AS GTTCTT
RET-EcoRI-S CCAAAG
RET-XbaI-AS CACTCT
RET-Fwd GATGG
RET-Rev ACCTGG
GAPDH-Fwd AGAAG
GAPDH-Rev AGGGG
RET UTR-wt-S: GTGTGT
RET UTR-MUT-AS: CTTCAT
RET UTR-MUT-S: CCGCCA
RET UTR-wt-AS: CTGACTgene. For miR-129-5p expression, miRNA speciﬁc forward primer
(miR-129-5p-Fwd) and the universal reverse primer (Rev) were
used with U6 snRNA for normalization. All reactions were
performed using Applied Rotor-Gene 6000 Real Time PCR System
(Corbett Research, Mortlake, Australia) in triplicate and the levels
of gene expression were calculated by relative quantiﬁcation
method. All primers used were purchased from AuGCT Biotechnol-
ogies (Beijing, China) and shown in Table 1.
2.3. Western blot analysis
Total proteins from clinical tissues were extracted using Total
Protein Extraction Kit (Applygen Technologies Inc, Beijing, China)
and cellular proteins were prepared using RIPA buffer (Beyotime,
Jiangsu, China). Then total proteins were separated by 10%
SDS–PAGE gel and transferred to nitrocellulose membranes. The
membranes were probed with the rabbit anti-RET and anti-GAPDH
antibodies (Sigma–Aldrich, MO, USA).
Rabbit anti-AKT and anti-phosphor-Akt (Ser473) antibody (Bio-
legend, CA, USA) were also used to detect the expression of AKT
(phosphorylation-state independent) and the phosphorylated form
of AKT (p-AKT). Proteins were visualized by HRP-conjugated goat
anti-rabbit secondary antibody and the enhanced chemilumines-
cence kit (Amersham Corp, Buckinghamshire, United Kingdom).
Quantity One software (Bio-Rad, CA, USA) was used to analyze
and quantify the expression of proteins of interest.
2.4. Plasmids construction
To generate the miR-129-5p expression plasmid, pcDNA3.1/pri-
miR-129-5p (Pri-miR-129-5p), a 250 bp fragment containing the
precursor of miR-129-5p, mir-129-1 (MI0000252), was ampliﬁed
by PCR using Pri-miR-129-5p-S and Pri-miR-129-5p-AS and cloned
into the pcDNA3.1 vector using the BamHI and EcoRI sites. The RET
full coding sequence (NM_020975) was ampliﬁed from total RNA
of TT cells and then used to construct the expression vector
pcDNA3.1/RET in two parts. The ﬁrst part was ampliﬁed with
RET-HindIII-S and RET-EcoRI-AS and inserted into the pcDNA3.1
vector using the HindIII and EcoRI sites. Then the second part
was obtained by RET-EcoRI-S and RET-XbaI-AS and then inserted
behind the ﬁrst part using the EcoRI and XbaI sites, thus generating
pcDNA3.1/RET vector. The pcDNA3.1 vector was used as a negative
control plasmid. All the primers used were provided in Table 1.ce (50–30)
TCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGCAAGC
GCGGTCTGGGCTTGC
TCCAGTGCAGGGTCCGAGGTGCACTGGATACGACAAAATATGG
GTGCTCGCTTCGGCAGC
GGTCCGAGGT
ATCCGACCCGGTCTTCTTGGTA
TTCACTGTTCTTGGGTTTGC
GCTTGCCACCATGGCGAAGGCGACGTCCGGTGC
CCGAGGGAATTCCCACTTTGG
TGGGAATTCCCTCGGAAGAAC
CTAGATTAACTATCAAACGTGTCCATTAAT
CACTAACACTGGG
GAACTGAACACG
GCTGGGGCTCATTTG
CCATCCACAGTCTTC
TTAAACCAGGTGGCAGACTCGTT
GTTTAAATTATATAGGCTTGTTTGGCGG
AACAAGCCTATATAATTTAAACATGAAG
CTAGACAGGTCATCAGGGCCAGC
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Brieﬂy, TT and MZ-CRC-1 cells (0.4  104) were plated in
96-well plates (Costar, CA, USA). After overnight incubation, cells
were transfected and incubated for another 24, 48 or 72 h. Then
cell proliferation was measured by MTT assays and the absorbance
at 570 nm (A570) was read using a Bio-Radmicroplate reader (Her-
cules, CA, USA). Each group was repeated in triplicate.
2.6. Cell apoptosis
Cells were plated in 6-well plates (6  105 cells/well) and trans-
fected in triplicate. Forty-eight hours after transfection, cells were
trypsinized and analyzed for cell apoptosis using the annexin V-PE/
7-aminoactinomycin D (7-AAD) apoptosis detection Kit (Keygen-
tec, Nanjing, China) following the manufacturer’s protocol.
2.7. Cell migration assays
A total of 5  104 cells (in 0.2 ml RPMI 1640 with 5% FBS) were
seeded into the upper part of a Transwell chamber (Corning, MA,
USA). Another 600 ll of RPMI1640 containing 20% FBS was addedFig. 1. MiR-129-5p inhibited the expression of RET by directly binding to its 30UTR. (A)
miR-129-5p target site. The mutant miR-129-5p targeted sequences (in red) in the mutat
5p, was transfected into TT and MZ-CRC-1 cells, with pcDNA3.1 as a negative control pla
(B), RET mRNA (C) and protein level (D) were measured by qRT-PCR and Western blo
respectively. (E) TT and MZ-CRC-1 cells were transfected with wild-type or mutant RET 30
miR-129-5p or pcDNA3.1 for 48 h. The graph depicts averaged results from three experto the lower portion of the chamber as a chemo attractant. After
incubating for 48 h, chambers were washed with PBS, ﬁxed in
100%methanol and stained with crystal violet. Then, cells migrated
across the membrane were counted in ﬁve random visual ﬁelds. All
assays were performed three independent times in triplicate.
2.8. In vivo tumorigenesis assay
For in vivo tumorigenesis assay, 5  106 TT or MZ-CRC-1 cells
transiently transfected with pcDNA3.1/pri-miR-129-5p or pcDNA
3.1 were suspended in 100 ll of serum-free RPMI 1640 and then
injected subcutaneously in the right posterior ﬂank of the female
BALB/c-nude mice at 6–7 weeks of age (10 mice in each group).
Ten days later, tumor growth was monitored and recorded by mea-
suring tumor length and width every three day, and tumor volume
was calculated according to 1/2  length width2. After 25 days,
mice were sacriﬁced for evaluation.
2.9. Target prediction and luciferase activity assay
MiRNAs targeting RET mRNA (NM_020975) was predicted by a
combination of TargetScan (www.targetscan.org) and microrna.orgBioinformatic prediction indicates that 30UTR of the RET mRNA contains a putative
ed 30UTR of RET are also shown. (B–D) MiR-129-5p expression vector, Pri-miR-129-
smid. Forty-eight hours later, cells were harvest and the expression of miR-129-5p
t analysis. U6 snRNA, GAPDH mRNA or protein level was used for normalization,
UTR luciferase reporter vector only or a combination of each reporter vector and Pri-
iments. Data represent means ± S.D. ⁄P < 0.05.
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dicted to interact with miR-129-5p was ampliﬁed using paired
primers RET UTR-wt-S and RET UTR-wt-AS and cloned into the
PmeI and XbaI sites of pmirGLO vector (Promega, Madison, WI,
USA). The mutant RET 30UTR fragment was also generated by
site-directed mutagenesis using PCR with another two primers,
RET UTR-MUT-S and RET UTR-MUT-AS. The two constructs were
sequenced and named RET 30UTR and Mut-RET 30UTR. For reporter
assays, cells were cultured in 24-well plates and transfected with
30UTR or mutant 30UTR luciferase reporters only, or cotransfected
with Pri-miR-129-5p and each luciferase reporter. Each assay
was performed in triplicate. Forty-eight hours following transfec-
tion, cells were harvested and analyzed for luciferase activity using
the Dual-Glo Luciferase Assay System (Promega, WI, USA) and a
MicroLumatPlus LB96V luminometer (Berthold, USA). Relative
luciferase activity was calculated as ratio of the raw ﬁreﬂy lucifer-
ase activity and the renilla luciferase activity.
2.10. Statistical analysis
Each experiment was repeated at least three times. All data
were presented as mean ± S.D. The difference between means
was analyzed with Student’s t test or analysis of variance (ANOVA).
All tests performed were two-sided. P < 0.05 was considered to be
statistically signiﬁcant.Fig. 2. Inverse correlation between miR-129-5p level and the expression of RET mRNA an
RET mRNA (B) and RET protein (C and D) in twelve pairs of MTC tissue samples (N) and the
qRT-PCR and Western blot analysis, with U6 snRNA, GAPDH mRNA or protein level as th
parts, while the expression of cell lines refers to N1 sample. The relative expression was
average expression level of MTC tissues. (E and F) The relationship between miR-129-5p a3. Results
3.1. MiR-129-5p negatively regulates the expression of RET in MTC
cells
To investigate if there were some miRNAs which could regulate
the expression of RET, computer algorithms (TargetScan and
microRNA.org) were used. And miR-129-5p was found to have
the identical 7 nucleotides of the 50 seed region which are comple-
mentary to bases 398–405 of the RET 30UTR (Fig 1A). Considering a
previous study has reported that miR-129-5p was able to induce
cell death in thyroid cancer cells [14], we speculated that miR-
129-5p may potentially target RET. To ascertain this, we employed
a gene over-expression approach to examine the effect of miR-129-
5p on RET protein and mRNA expression. TT and MZ-CRC-1 cells
were transfected with miR-129-5p over-expression vector,
pcDNA3/pri-miR-129-5p (Pri-miR-129-5p), which has been veri-
ﬁed to elevate the level of miR-129-5p (Fig 1B), and then RET
mRNA and protein expression were measured by qRT-PCR and
Western blot analysis, respectively. As shown in Fig. 1C and D,
over-expression of miR-129-5p decreased the endogenous RET
mRNA and protein level in TT and MZ-CRC-1 cell lines. In addition,
we used luciferase reporter assays to validate the direct binding
site of the 30UTR of RET mRNA by miR-129-5p. We constructedd protein in the MTC tissues and cell lines. (A–D) The expression of miR-129-5p (A),
ir adjacent normal parts (C), as well as TT and MZ-CRC-1 cell lines, were detected by
e internal controls. Relative expression of each MTC sample refers to their normal
shown. N-all: the average expression level of all adjacent normal tissues; C-all: the
nd RET mRNA (E) or protein level (F) are analyzed by Pearson’s correlation. ⁄P < 0.05.
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mutant putative target site of the RET 30UTR (shown in Fig 1A)
and transfected them into TT cell respectively, together with Pri-
miR-129-5p or pcDNA3.1. 48 h later, the luciferase activities were
tested. It was found that miR-129-5p can signiﬁcantly down-regu-
late the luciferase activities of the RET 30UTR reporter but not the
mutant RET 30UTR reporter relative to the negative control group
(Fig. 1E). This suggested that the target site in the 30UTR of RET
mRNAwas essential for the regulation of miR-129-5p. These obser-
vations demonstrate that miR-129-5p binds directly to the 30UTR
of RET and represses RET expression.
3.2. MiR-129-5p inversely correlates with RET expression in RET
tissues and cell lines
On the basis of the above result that miR-129-5p down-regu-
lated the expression of RET in MTC cell lines, we then investigated
the relationship between miR-129-5p and RET genes in MTC tis-
sues. We employed qRT-PCR and Western blot methods to analyze
the expression levels of miR-129-5p and RET mRNA and protein in
12 pairs of MTC tissues and its adjacent normal parts, as well as TT
and MZ-CRC-1 cell lines. The results showed that miR-129-5p was
remarkably down-regulated, whereas RET mRNA and protein
levels were obviously up-regulated in MTC tissue samples and cellFig. 3. The Effects of miR-129-5p on the viability, apoptosis and migration of MTC cells. (
negative control plasmid. In the indicated time periods after transfection, cell viability w
above cells at 48 h post-transfection were subjected to detect cell apoptosis (B) and m
Transwell migration assays. The representative photographs are shown (40 magniﬁcatlines, compared to the matched normal tissue samples (Fig. 2A–D).
Furthermore, the correlation of miR-129-5p expression and the
mRNA or protein level of RET also indicated that miR-129-5p
was inversely correlated with RET mRNA (Fig 2E, r = 0.7546)
and protein expression (Fig 2F, r = 0.7660) in MTC tissues and cell
lines.3.3. MiR-129-5p inhibits cell growth, induces cell apoptosis and
reduces cell invasion in vitro
To investigate the role of miR-129-5p, we checked the inﬂuence
of miR-129-5p on the cell viability, apoptosis and migration of MTC
cells in vitro through increasing the expression level of miR-
129-5p in TT and MZ-CRC-1 cell lines. The MTT results indicated
that over-expression of miR-129-5p signiﬁcantly suppressed the
cell viability, and both cell lines showed a time-dependent growth
inhibition (Fig 3A). To determine the mechanism of cell-growth
inhibition in MTC cells by miR-129-5p, we analyzed whether
miR-129-5p caused cell apoptosis by FACS analysis using the an-
nexin V-PE/7-AAD apoptosis detection Kit. It was found that the
potency of cell apoptosis was markedly different and more pro-
nounced in MTC cells with higher level of miR-129-5p comparing
to the control group (Fig 3B). In addition, we also detected theA) TT and MZ-CRC-1 cells were transfected with pri-miR-129-5p, with pcDNA3.1 as
as evaluated using MTT assays by measuring the absorption at 570 nm. (B–D) The
igration ability (C and D) by annexin V-PE/7-AAD staining followed by FACS and
ion). The experiments were repeated three times independently. ⁄P < 0.05.
Fig. 4. Ectopic expression of RET rescues the effects of MTC cells exerted by over-expression of miR-129-5p. (A and B) A combination of RET expression vector pcDNA3.1/RET
(RET) or its negative control vector pcDNA3.1 (Vector) and Pri-miR-129-5p was transfected into the TT and MZ-CRC-1 cells. Cells transfected with Pri-miR-129-5p only was
used as the blank control group. The expression of RET, AKT and p-AKT in three groups were detected by Western blot analysis (A). GAPDH protein level was used as the
loading control and the relative expression were shown (B). (C–F) The viability (C), apoptosis (D) and migration ability (E and F) of the above groups were also detected
respectively as mentioned previously. The representative photographs (40 magniﬁcation) and its relative results are shown. ⁄P < 0.05.
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by Transwell migration assays. The results showed that the num-
ber of cells migrating across the membranes was decreased dra-
matically after the cells were transfected with Pri-miR-129-5p(Fig. 3C and D). These data indicated that miR-129-5p reduced
the viability, induced cell apoptosis and suppressed the migration
of MTC cells in vitro, suggesting a potential tumor suppressive role
of miR-129-5p.
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caused by miR-129-5p in MTC cells
To further conﬁrm that the effect of miR-129-5p on MTC cells
was dependent on the inhibition of RET expression, we transfected
RET expression vector, pcDNA3.1/RET, into the MTC cell lines with
high levels of miR-129-5p to counteract the function of miR-129-
5p. After the RET expression was validated by Western blot
analysis in MTC cells (Fig 4A and B), we analyzed the cell viability,
apoptosis and migration ability of the above groups, respectively.
The results showed that ectopic expression of RET was able to res-
cue the decreased cell viability, the increased cell apoptosis and the
suppressed migration ability caused by over-expression of miR-
129-5p (Fig. 4C–F). In addition, we evaluated the effects of
miR-129-5p on AKT activation by measuring the expression level
of total AKT and phosphorylated AKT using Western blot analysis.
The results showed that ectopic expression of miR-129-5p lead to
the lower levels of phosphorylated AKT, wheraeas over-expression
of RET restored the level of phosphorylated AKT decreased by miR-
129-5p (Fig. 4A and B). All groups have no effects on the expression
of total AKT (Fig. 4A). These data suggested that the effects of MTC
cells induced bymiR-129-5p were achieved by direct inhibiting the
expression of RET and decreasing the phosphorylated AKT.
3.5. MiR-129-5p suppress the tumor growth through inhibiting RET
in vivo
We also investigated the effects of miR-129-5p on tumor
growth of MTC cells through an in vivo tumorigenesis assays. TTFig. 5. MiR-129-5p inhibits the tumor growth of MTC cells in nude mice model. TT a
subcutaneously into the right posterior ﬂank of the female BALB/c-nude mice. Tumor volu
photographs of dissected tumors from nude mice (A) and the curve of tumor growth (B
detected by qRT-PCR and Western blot analysis, with U6 snRNA and GAPDH protein as
shown. ⁄P < 0.05.or MZ-CRC-1 cells were transfected with Pri-miR-129-5p or
pcDNA3.1 vectors and then injected subcutaneously into the
BALB/c nude mice respectively. As shown in Fig 5A and B, the mice
inoculated with cells with a high level of miR-129-5p had a signif-
icant reduction in the tumor volumes, compared with that inocu-
lated with pcDNA3.1-transfected cells. And the expression level
of miR-129-5p in tumor tissues with Pri-miR-129-5p transfection
group was higher than that in tumor tissues with pcDNA3.1 trans-
fection group (Fig. 5C), which was consistent with the decreased
RET level in Pri-miR-129-5p transfection group (Fig. 5D). All of
these data suggested that enforced expression of miR-129-5p
can signiﬁcantly suppressed MTC cell growth in vivo through
inhibiting RET protein level, indicating a tumor suppressor of
miR-129-5p.
4. Discussion
Dysregulation of the RET pathway is crucial for the develop-
ment of MTC [3] and the dysregulation of miRNA expression proﬁle
has also been reported in MTC cells [9,13]. On the basis of these, we
postulate the existence of a possible mechanism that RET genes are
regulated by miRNAs. In our experiments, bioinformatic prediction
and luciferase reporter assays were used and veriﬁed that the en-
forced expresson of miR-129-5p resulted in the inhibited expres-
sion of RET in MTC cells through a direct interaction between
miR-129-5p and the 30UTR of RET. These suggested that RET was
a direct target gene of miR-129-5p. Thus, we found a new way of
regulating RET gene, that is RET was inhibited by miR-129-5p
through directly binding the 30UTR of its mRNA.nd MZ-CRC-1 cells transfected with Pri-miR-129-5p were suspended and injected
me was monitored by measuring the length and width of the tumor. Representative
) are shown. MiR-129-5p (C) and RET protein (D) in the transplanted tumors was
internal controls. The representative image and the relative expression level were
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[15]. It has been reported to be down-regulated in gastric cancer
[16], colorectal cancer [17] and hepatocellular carcinoma [18]
and act as a tumor suppressor. However, it has also been shown
to be up-regulated laryngeal squamous cell carcinoma [19] and
function as an oncogene. Here, we found that miR-129-5p was
down-regulated in MTC tissues and cell lines. Ectopic expression
of miR-129-5p leaded to the decreased cell viability, induction of
cell apoptosis and the suppressed migration ability in vitro. And
restoration of RET protein expression counteracted the effects
caused by over-expression of miR-129-5p. Furthermore, miR-
129-5p signiﬁcantly suppressed MTC cell growth in vivo, in parallel
with the inhibited level of RET protein. All of these data indicated
that miR-129-5p functioned as a tumor suppressor in MTC cells by
inhibiting RET proto-oncogene, which was consistent with the pre-
vious study [14].
Moreover, we investigated the possible mechanism through
which miR-129-5p exerted its function as a tumor suppressor in
MTC cells. Since it has been reported that RET gene functions as
an oncogene through mediating the activation of AKT pathway
[20], we measured the status of AKT phosphorylation in MTC cells
with different levels of miR-129-5p. The results showed that in-
creased level of miR-129-5p signiﬁcantly inhibited the expression
of RET and phosphorylated AKT, and over-expression of RET in cells
with high levels of miR-129-5p restored the status of AKT phos-
phorylation which was decreased by miR-129-5p. These data
indicated that the tumor suppressor role of miR-129-5p was re-
lated with decreased RET expression and suppressed AKT
phosphorylation.
However, many details need further validation in the future. Be-
cause the relative normal tissue used in this study is the parts dis-
tant from primary disease loci, there is a possibility that the normal
parts may not be normal c-cells, fromwhich MTC is derived. There-
fore, the differential expression between MTC tissues and their
adjacent relative normal parts could be related with differences
in tissue types.
In short, we here found miR-129-5p was down-regulated and
inhibited directly the expression of RET in MTC cells. In addition,
we showed that miR-129-5p inhibited cell growth, induced cell
apoptosis and suppressed the ability of cell migration, suggesting
a tumor suppressor role in medullary thyroid cancers harboring
oncogenic point mutation of RET. These will be helpful for the bet-
ter understanding of carcinogenesis and could represent a new
therapeutic target for the treatment of these tumors.
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